Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3024 - A Multicentre Phase I/II Study of TAS-102 with Nintedanib in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (N-TASK FORCE: EPOC1410)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer


Kentaro Yamazaki


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


K. Yamazaki1, Y. Kuboki2, E. Shinozaki3, H. Hara4, Y. Komatsu5, T. Nishina6, K. Yamaguchi3, S. Yuki7, H. Bando2, M. Asayama8, T. Tsushima1, S. Hamauchi1, H. Nakatsumi7, T. Kajiwara6, M. Wakabayashi9, S. Nomura10, A. Sato9, T. Doi11, A. Ohtsu12, T. Yoshino2

Author affiliations

  • 1 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-0933 - Shizuoka/JP
  • 2 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 3 Department Of Gastroenterology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 4 Department Of Gastroenterology, Saitama Cancer Center Hospital, Saitama/JP
  • 5 Department Of Cancer Chemotherapy, Hokkaido University Hospital Cancer Centre, 060-8638 - Sapporo/JP
  • 6 Department Of Gastrointestinal Medical Oncology, Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 7 Department Of Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 8 Department Of Gastroenterology, Saitama Cancer Center, 3620806 - Ina/JP
  • 9 Office Of Clinical Research Support, National Cancer Center Hospital East, Chiba/JP
  • 10 Office Of Clinical Research Support, National Cancer Center Hospital East, Kashiwa/JP
  • 11 Department Of Experimental Therapeutics, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 12 Director, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP


Abstract 3024


TAS-102 demonstrated significant improvement in overall survival (OS) over placebo in patients (pts) with metastatic colorectal cancer (mCRC). Nintedanib is a triple angiokinase inhibitor of VEGFR (1, 2, 3), PDGFR (a, β), and FGFR (1, 2, 3). In preclinical models, the combination of TAS-102 plus nintedanib demonstrated enhanced activity against CRC compared with either drug alone. This study was conducted to determine the recommended phase II dose (RP2D) and evaluate the efficacy and safety in pts with mCRC refractory to standard therapies. RP2D was determined nintedanib 200mg BID every day adding to standard-dose of TAS-102 in the phase I part (Nishina T, et al. ESMO 2016). We present here on the efficacy and safety data from the ongoing study.


The key eligibility criteria were pts with mCRC refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-angiogenesis inhibitor and anti-EGFR antibody (if wild-type RAS) and without prior regorafenib. Primary endpoint was investigator-assessed progression-free survival (PFS) rate at 16 weeks in pts treated with RP2D. Using a single stage binomial design, this study required 52 pts, with the PFS rate at 16 weeks of 40% deemed promising and 25% unacceptable (alpha=0.1; beta=0.2).


From August 2015 to August 2016, 55 pts were enrolled. Among them, 52 pts received the RP2D as full analysis set. The PFS rate at 16 weeks was 38.5% (80% confidence interval: 29.3–48.3%). Four pts (7.7%) achieved a partial response, median PFS and disease control rate were 3.7 months and 69.2%, respectively. Median OS was 9.2 months. The median number of treatment cycles was 4 (range 1 - 14). The most common grade 3 or worse treatment-associated adverse events were neutropenia (59.6%), anemia (17.3%), thrombocytopenia (11.5%) and increased liver enzymes (AST: 9.6%, ALT: 7.7%; asymptomatic reversible elevation without any bilirubin elevation). Febrile neutropenia occurred in two (3.8%) pts. There was no treatment-related death.


Standard-dose of TAS-102 with nintedanib 200 mg BID showed promising antitumor activity with acceptable toxicity for mCRC pts.

Clinical trial identification


Legal entity responsible for the study

Exploratory Oncology Research & Clinical Trial Center


Taiho Pharmaceutical and Boehringer Ingelheim


K. Yamazaki: Honoraria: Bayer Yakuhin, Bristol-Myers Squibb Japan, Chugai Pharma, Daiichi Sankyo, Lilly Japan, Merck Serono, Takeda, Taiho Pharmaceutical, and Yakult Honsha; research funding: Bristol-Myers-Squibb Japan and Sanofi. Y. Kuboki: Corporate-sponsored research: Takeda; Other Substantive Relationships (Taiho Pharmaceutical, Bayer: (Honoraria)) E. Shinozaki: Other Substantive Relationships (Taiho, Merck Serono, Takeda, Ono, Chugai, Yakult, Bayer (Honoraria)) H. Hara: Advisory Board Ono, Chugai Corporate-sponsored-research AstraZeneca, Chugai, Merck Serono, MSD, Ono, Taiho, Takeda, Boehringer Ingelheim, Dainippon Sumitomo, Daiichi Sankyo, Lilly Other Chugai, Taiho, Merck Serono, Yakult Honsha, Lilly(Honoraria) Y. Komatsu: Corporate-sponsored-research (Taiho Chugai Pharma Novartis MSD Ono Pharmaceutical Bayer Yakult Lilly) Other Substantive Relationships (Novartis, Pfizer, Bayer(Honoraria)) (Taiho Chugai Lilly Novartis Merck Pfizer, Bayer (Speaker bureau)) K. Yamaguchi: Corporate-sponsored-research (Taiho MSD daiichi-sankyo Ono Merck Bristol Dainipponn-sumitomo Beringer Yakurut Honsha) Other Substantive Relationships (Taiho Takeda Chugai Merck Yakurut-Honsha Lilly(Speaker bureau)) M. Asayama: Corporate-sponsored research (Takeda) T. Tsushima: Other Substantive Relationships (Chugai Pharmaceutical, Takeda Pharmaceutical, Ono Pharmaceutical, Taiho Pharmaceutical(Honoraria)) S. Nomura: Other Substantive Relationships Asahi-Kasei pharma (immediately family member; employment) A. Sato: Corporate-sponsored-research (Taiho Dainippon Sumitomo Pharma Novartis Ono Pharmaceutical Boehringer Ingelheim Bayer) T. Doi: Advisory Board(Lilly, Chugai, Kyowa Hakko Kirin, Novartis, MSD, Daiichi Sankyo, Amgen) Corporate-sponsored-research (Taiho, Merck, Astellas, Janssen, Takeda, Pfizer, Lilly, Sumitomo Group, Bayer, Chugai, Kyowa Hakko Kirin, Boehringer, Novartis, MSD, Daiichi Sankyo, Celgene) A. Ohtsu: Corporate-sponsored-research BMS Other Substantive Relationships Celgene (immediately family member; employment) T. Yoshino: Corporate-sponsored-research GlaxoSmithKline K.K.Boehringer Ingelheim GmbH All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.